Ocuphire Pharma
secondary safety findings | Ocuphire Pharma
Company
Deck Type
Deck date
March 2021
Slide
18 of 29
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
summary of safety findings there were no deaths serious aes or withdrawals due to aes of treated subjects reported aes the only occurring in of subjects treated with was conjunctival hyperemia placebo conjunctival hyperemia was observed to be mild and transient visual acuity distance and near was not adversely affected by over subjects have been treated with and evaluated at hours in the trials satisfying regulatory requirements for drug safety exposure for the acute indication | Ocuphire Pharma
Investor Day
January 2022
safety findings after dilation with mydriatic agent | Ocuphire Pharma
Related slides by other companies
MAIA Biotechnology
Investor Presentation
July 2023
thio trial patients dosed to date | MAIA Biotechnology
MAIA Biotechnology
Investor Presentation
November 2023
thio trial patients dosed to date | MAIA Biotechnology
argenx SE
Results
July 2023
positive topline results primary stage a response rate safety and tolerability adhere | argenx SE
ATAI
Investor Presentation
October 2022
phase study design prospective randomized double blind placebo controlled study of single and multiple ascending doses of part single ascending dose part multiple ascending dose treatment safety treatment safety up to healthy subjects up to cohorts to up to healthy subjects up to cohorts to every hours for days adverse events were mild in most cases with no severe or serious adverse events or dose relation with minimal sedation or dizziness administered evaluate tolerability | ATAI
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights